"Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
| Descriptor ID |
D013926
|
| MeSH Number(s) |
D12.644.276.374.410.240.750 D12.776.395.240.750 D12.776.467.374.410.240.750 D23.529.374.410.240.750
|
| Concept/Terms |
Thrombopoietin- Thrombopoietin
- Megakaryocyte Colony Stimulating Factor
- Megakaryocyte Growth and Development Factor
- Thrombocytopoietin
- mpl Ligand
- Ligand, mpl
- Myeloproliferative Leukemia Virus Oncogene Ligand
- Thrombocytopoiesis-Stimulating Factor
- Thrombocytopoiesis Stimulating Factor
- c-mpl Ligand
- Ligand, c-mpl
- MGDF Factor
|
Below are MeSH descriptors whose meaning is more general than "Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Thrombopoietin".
This graph shows the total number of publications written about "Thrombopoietin" by people in this website by year, and whether "Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombopoietin" by people in Profiles.
-
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia. Blood Adv. 2023 02 14; 7(3):396-405.
-
Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Pediatr Blood Cancer. 2020 11; 67(11):e28630.
-
Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019 07; 94(7):741-750.
-
Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica. 2019 11; 104(11):2283-2291.
-
Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-?. Blood. 2019 05 09; 133(19):2043-2055.
-
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
-
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018 Mar; 5(3):e117-e126.
-
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913.
-
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13.
-
Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis. Pediatr Blood Cancer. 2016 08; 63(8):1484-7.